Combination
therapy has been widely studied due to its promising applications in
tumor therapy. However, a sophisticated nanoplatform and sequential irradiation with different
laser sources for
phototherapy complicate the treatment process. Unlike the integration of therapeutic agents, we report a FeS2@SRF@BSA nanoplatform for the combination of chemo-combined
photothermal therapy (PTT) enhanced
photodynamic therapy (
PDT) and chemodynamic
therapy (CDT) to achieve an "all-in-one" therapeutic agent. Ultrasmall FeS2 nanoparticles (NPs) with a size of 7 nm exhibited higher Fenton reaction rates due to their large specific surface areas. A photodynamic reaction could be triggered and could generate 1O2 to achieve
PDT under 808 nm irradiation. FeS2 NPs also exhibited the desired photothermal properties under the same wavelength of the
laser. The Fenton reaction and photodynamic reaction were both significantly improved to accumulate more
reactive oxygen species (ROS) with an increase of temperature under
laser irradiation. Besides, loading of the chemotherapeutic drug
sorafenib (SRF) further improved the efficacy of
tumor treatment. To realize long blood circulation,
bovine serum albumin (BSA) was used as a carrier to encapsulate FeS2 NPs and SRF, remarkably improving the biocompatibility and
tumor enrichment ability of the nanomaterials. Additionally, the
tumors on mice treated with FeS2@SRF@BSA almost disappeared under 808 nm irradiation. To sum up, FeS2@SRF@BSA NPs possess good biocompatibility, stability, and sufficient therapeutic efficacy in combination
therapy for
cancer treatment. Our study pointed out a smart design of the nanoplatform as a multifunctional therapeutic agent for combination
cancer therapy in the near future.